The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)
Abstract
To learn about the carboxy-terminal extent of amyloid beta-protein (A beta) composition of senile plaques (SPs) in the brain affected with Alzheimer's disease (AD), we employed two end-specific monoclonal antibodies as immunocytochemical probes: one is specific for A beta 40, the carboxyl terminus of A beta 1-40, while the other is specific for A beta 42(43). In the AD cortex, all SPs that were labeled with an authentic antibody were A beta 42(43) positive, while only one-third of which, on the average, were A beta 40 positive. There was a strong correlation between A beta 40 positivity and mature plaques. Two familial AD cortices with the mutation of beta-amyloid protein precursor 717 (beta APP717) (Val to Ile) showed a remarkable predominance of A beta 42(43)-positive, A beta 40-negative plaques. Diffuse plaques, representing the earliest stage of A beta deposition, were exclusively positive for A beta 42(43), but completely negative for A beta 40.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These observations indicate that Aps ending at Ap42(43), which are a minor component of the Ap in human cerebrospinal fluid and plasma, are critically important in AD where they deposit selectively in plaques of all kinds.”
From Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain (1995) · cites this paper as [21]
In the citing paper
“The immunocytochemical results shown here and in a recent report by Iwatsubo et al. (21) demonstrate that BC-05 intensely stains all types of senile plaques, that vessels are stained by both BC-OS and BA-27, and that BA-27 stains plaques poorly, in many cases only faintly staining occasional cored plaques (Fig. 3).”
From Amyloid β Protein (Aβ) in Alzheimeri's Disease Brain (1995) · cites this paper as [21]
In the citing paper
“From studies of trisomy 21 brains (Iwatsubo et al., 1994), it is generally believed that, in human AD, A deposition begins with the formation of diffuse plaques.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“there is good evidence that A1-42 is deposited early and selectively in senile plaques (Iwatsubo et al., 1994).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“In contrast, Aβ40, the major Aβ peptide secreted by cells, appears to be the predominant species deposited in the amyloid deposits in the cerebral vasculature (congophillic angiopathy, CAA) (Gravina et al., 1995; Iwatsubo et al., 1994).”
From Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice (2005) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“These data provide definitive in vivo confirmation of predictions inferred from (1) in vitro studies of Aβ aggregation, (2) effects of PS and certain APP mutations on Aβ production and deposition, and (3) analyses of Aβ peptides in the human AD brain (Gravina et al., 1995; Iwatsubo et al., 1994).”
From Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice (2005) · cites this paper as Iwatsubo et al., 1994
In the citing paper
“Indeed, Aβ42 is the main component of amyloid plaques and is shown to be neurotoxic [30].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [30]
In the citing paper
“the slightly longer Aβ42 species that is specifically linked with FAD is also the first Aβ species deposited in cerebral plaques [82].”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [82]
In the citing paper
“The subsequent development of antibodies directed at the free C-terminal ends of Aβ40 or Aβ42 [82] led to the ability to differentiate Aβ from APP labeling”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [82]
Citations
Cites
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Jarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Cited by
Sorted by citations
Items 801–900 of 1,000
Suárez‐Calvet, M., Belbin, O., Pera, M., Badiola, N., Magrané, J., Guardia‐Laguarta, C., Muñoz, L., Colom‐Cadena, M., Clarimón, J., & Lleó, A. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12466 · Cited by 44
Klaver, D. W., Wilce, M. C. J., Cui, H., Hung, A. C., Gasperini, R., Foa, L. C., & Small, D. H. (2010) · Biological Chemistry · doi:10.1515/bc.2010.089 · Cited by 41
Tomi, M., Zhao, Y., Thamotharan, S., Shin, B., & Devaskar, S. U. (2012) · Brain Research · doi:10.1016/j.brainres.2012.11.050 · Cited by 40
Calmodulin antagonizes amyloid-β peptides-mediated inhibition of brain plasma membrane Ca2+-ATPase
Berrocal, M., Sepúlveda, M. R., Vázquez-Hernández, M., & Mata, A. M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.013 · Cited by 41
Olofsson, A., Lindhagen‐Persson, M., Vestling, M., Sauer-Eriksson, A. E., & Öhman, A. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07113.x · Cited by 42
Progress in the development of new drugs in Alzheimer's disease
Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B. (2011) · The Journal of nutrition, health and aging · doi:10.1007/s12603-011-0012-x · Cited by 32
Meunier, J., Villard, V., Givalois, L., & Maurice, T. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.10.033 · Cited by 41
Bros, P., Delatour, V., Vialaret, J., Lalère, B., Barthélemy, N. R., Gabelle, A., Lehmann, S., & Hirtz, C. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-1048 · Cited by 41
Transmembrane Substrate Determinants for γ-Secretase Processing of APP CTFβ
Fernandez, M. A., Biette, K. M., Dolios, G., Seth, D., Wang, R., & Wolfe, M. S. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00718 · Cited by 42
Zhang, Y., Xie, J., Xu, X., Hu, J., Xu, T., Jin, S., Yang, S., & Wang, J. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-018-00336-7 · Cited by 44
Mao, S., Huang, C.-P., Lan, H., Lau, H.-G., Chiang, C., & Chen, Y. (2022) · Journal of Dental Sciences · doi:10.1016/j.jds.2022.07.001 · Cited by 43
Mann, D. M. A., McDonagh, A. M., Pickering-Brown, S. M., Kowa, H., & Iwatsubo, T. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01785-2 · Cited by 41
Self-citationRational Design and Synthesis of Potent Dibenzazepine Motifs as β-Secretase Inhibitors
Al‐Tel, T. H., Al‐Qawasmeh, R. A., Schmidt, M. F., Al-Aboudi, A. F., Rao, S. N., Sabri, S. S., & Voelter, W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9008482 · Cited by 41
Inflammation in Neurodegenerative Disorders: Friend or Foe?
Galimberti, D., Fenoglio, C., & Scarpini, E. A. (2008) · Current Aging Science · doi:10.2174/1874609810801010030 · Cited by 41
γ-Secretase Cleavage Site Specificity Differs for Intracellular and Secretory Amyloid β
Grimm, H. S., Beher, D., Lichtenthaler, S. F., Shearman, M. S., Beyreuther, K. T., & Hartmann, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210380200 · Cited by 40
Roßner, S., Beck, M., Stahl, T., Mendla, K. D., Schliebs, R., & Bigl, V. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00211.x · Cited by 41
Gandy, S., & Petanceska, S. S. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00031-4 · Cited by 40
Potent and selective isophthalamide S2 hydroxyethylamine inhibitors of BACE1
Kortum, S. W., Benson, T. E., Bienkowski, M. J., Emmons, T. L., Prince, D. B., Paddock, D. J., Tomasselli, A. G., Moon, J. B., LABORDE, A. L., & TenBrink, R. E. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.03.096 · Cited by 40
Formation of Toxic Amyloid Fibrils by Amyloid β‐Protein on Ganglioside Clusters
Matsuzaki, K. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/956104 · Cited by 40
Adenosine receptor signalling in Alzheimer’s disease
Trinh, P. N. H., Baltos, J., Hellyer, S. D., May, L. T., & Gregory, K. J. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09883-1 · Cited by 43
Central β‐amyloid peptide‐induced peripheral interleukin‐6 responses in mice
Song, D., Im, Y., Jung, J., Cho, J., Suh, H., & Kim, Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00121.x · Cited by 40
What is the dominant aβ species in human brain tissue? A review
Gregory, G. C., & Halliday, G. M. (2005) · Neurotoxicity Research · doi:10.1007/bf03033774 · Cited by 41
Murray, M., & Dickson, D. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt254 · Cited by 39
Petanceska, S. S., Seeger, M., Checler, F., & Gandy, S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741878.x · Cited by 40
Monogenetic determinants of Alzheimer's disease: APP mutations
Goate, A. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050218 · Cited by 41
Microglial cells and amyloid ? protein (A?) deposition: association with A?40-plaques
Mann, D. M. A., Iwatsubo, T., Fukumoto, H., Ihara, Y., Odaka, A., & Suzuki, N. (1995) · Acta Neuropathologica · doi:10.1007/bf00294808 · Cited by 40
Self-citationβ-Amyloid Enhances Glial Glutamate Uptake Activity and Attenuates Synaptic Efficacy
Ikegaya, Y., Matsuura, S., Ueno, S., Baba, A., Yamada, M. K., Nishiyama, N., & Matsuki, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203764200 · Cited by 39
Ordóñez‐Gutiérrez, L., Posado-Fernández, A., Ahmadvand, D., Lettiero, B., Wu, L., Antón, M., Flores, O., Moghimi, S. M., & Wandosell, F. G. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.07.027 · Cited by 40
Amyloid β Fibril Elongation by Monomers Involves Disorder at the Tip
Bacci, M., Vymětal, J., Mihajlovic, M., Caflisch, A., & Vitalis, A. (2017) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.7b00662 · Cited by 39
Azouz, M., Cullin, C., Lecomte, S., & Lafleur, M. (2019) · Nanoscale · doi:10.1039/c9nr06361g · Cited by 39
Nanoliposomes as a Therapeutic Tool for Alzheimer’s Disease
Ordóñez‐Gutiérrez, L., & Wandosell, F. G. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00020 · Cited by 40
Dynamic Blood Concentrations of Aβ1–40 and Aβ1–42 in Alzheimer’s Disease
Yang, Y.-H., Huang, L.-C., Hsieh, S.-W., & Huang, L.-J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00768 · Cited by 39
Aluminum and Tau in Neurofibrillary Tangles in Familial Alzheimer’s Disease
Mold, M. J., O’Farrell, A., Morris, B., & Exley, C. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210011 · Cited by 42
Sato, K., Watamura, N., Fujioka, R., Mihira, N., Sekiguchi, M., Nagata, K., Ohshima, T., Saito, T., Saido, T. C., & Sasaguri, H. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101004 · Cited by 38
Wickramasinghe, A., Xiao, Y., Kobayashi, N., Wang, S., Scherpelz, K. P., Yamazaki, T., Meredith, S. C., & Ishii, Y. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03346 · Cited by 41
The influence of diagnosis, intra- and inter-person variability on serum and plasma Aβ levels
Abdullah, L. I., Paris, D., Luis, C. A., Quadros, A., Parrish, J., Valdés, L., Keegan, A. P., Mathura, V. S., Crawford, F., & MULLAN, M. J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.09.058 · Cited by 39
Mok, S. S., Lošić, D., Barrow, C. J., Turner, B. J., Masters, C. L., Martin, L. L., & Small, D. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03539.x · Cited by 42
LeBlanc, A. C., & Goodyer, C. G. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721832.x · Cited by 39
Coughlan, C. M. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00036-x · Cited by 39
Thaker, U., McDonagh, A. M., Iwatsubo, T., Lendon, C. L., Pickering-Brown, S. M., & Mann, D. M. A. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00425.x · Cited by 39
Self-citationStrategies for Improving the Postmortem Neuropathological Diagnosis of Alzheimer’s Disease
Trojanowski, J. Q., Clark, C. M., Schmidt, M. L., Arnold, S. E., & LEE, V. M. ‐. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00075-4 · Cited by 39
Rhodin, J. A. G., Thomas, T. N., Clark, L. C., Garces, A. H., & Bryant, M. (2003) · Journal of Alzheimer s Disease · doi:10.3233/jad-2003-5403 · Cited by 40
Pathophysiological role of calpain in experimental demyelination
Shields, D. C., & Banik, N. L. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990301)55:5 · Cited by 64
Synapses, Microglia, and Lipids in Alzheimer’s Disease
Paasila, P. J., Aramideh, J. A., Sutherland, G. T., & Graeber, M. B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.778822 · Cited by 40
Ntsapi, C., Lumkwana, D., Swart, C., du Toit, A., & Loos, B. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.002 · Cited by 39
Elucidating the Molecular Determinants of Aβ Aggregation with Deep Mutational Scanning
Gray, V. E., Sitko, K. A., Kameni, F. Z. N., Williamson, M., Stephany, J. J., Hasle, N., & Fowler, D. M. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400535 · Cited by 39
Cerebral amyloid β(42) deposits and microvascular pathology in ageing baboons
Ndung'u, M., Härtig, W., Wegner, F., Mwenda, J. M., Low, R. W. C., Akinyemi, R., & Kalaria, R. N. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01246.x · Cited by 38
Advances on the Understanding of the Origins of Synaptic Pathology in AD
Lacor, P. N. (2007) · Current Genomics · doi:10.2174/138920207783769530 · Cited by 40
Hossain, S., Hashimoto, M., Katakura, M., Al Mamun, A., & Shido, O. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0620-9 · Cited by 38
Network Excitability Dysfunction in Alzheimer's Disease: Insights from In Vitro and In Vivo Models
Santos, S. F., Pierrot, N., & Octave, J. (2010) · Reviews in the Neurosciences · doi:10.1515/revneuro.2010.21.3.153 · Cited by 37
Nguyen, P. T., Kimura, T., Ho, S. A., Tran, A. H., Ono, T., & Nishijo, H. (2007) · Hippocampus · doi:10.1002/hipo.20281 · Cited by 37
Hoashi, T., Tamaki, K., & Hearing, V. J. (2009) · The FASEB Journal · doi:10.1096/fj.09-140921 · Cited by 39
Aggregation of Alzheimer Amyloid β Peptide (1−42) on the Multivalent Sulfonated Sugar Interface
Fukuda, T., Matsumoto, E., Onogi, S., & Miura, Y. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100053x · Cited by 38
Söderberg, L., Bogdanović, N., Axelsson, B., Winblad, B. G., Näslund, J., & Tjernberg, L. O. (2006) · Biochemistry · doi:10.1021/bi060331+ · Cited by 38
Progression of Alzheimer histopathological changes.
Duyckaerts, C. J., Colle, M.-A., Dessi, F., Piette, F., & Hauw, J. (1998) · PubMed · Cited by 38
Effects of chronic variable stress on cognition and Bace1 expression among wild-type mice
Cordner, Z. A., & Tamashiro, K. L. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.127 · Cited by 38
Molecular Pathology of Alzheimer’s Disease and Related Disorders
Ginsberg, S. D., Schmidt, M. L., Crino, P. B., Eberwine, J. H., Lee, V. M. ‐., & Trojanowski, J. Q. (1999) · Cerebral cortex · doi:10.1007/978-1-4615-4885-0_17 · Cited by 38
In vitro reconstitution of γ-secretase activity using yeast microsomes
Yagishita, S., Futai, E., & Ishiura, S. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.09.090 · Cited by 38
Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease
Zhang, Y., Hayes, A., Pritchard, A. L., Thaker, U., Haque, S. M., Lemmon, H. A., Harris, J. M., Cumming, A., Lambert, J., Chartier‐Harlin, M., et al. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.03.008 · Cited by 38
Self-citationZohar, O., Cavallaro, S., D’Agata, V., & Alkon, D. L. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(03)00182-7 · Cited by 30
Wilson, C., Doms, R. W., & Lee, V. M. ‐. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10776 · Cited by 37
Li, D., & Liu, C. (2023) · Structure · doi:10.1016/j.str.2023.08.006 · Cited by 39
Regulation of Cerebral Cholesterol Metabolism in Alzheimer Disease
Reiss, A. B., & Voloshyna, I. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318246d973 · Cited by 38
Synthetic ceramide analogues increase amyloid-β 42 production by modulating γ-secretase activity
Takasugi, N., Sasaki, T., Shinohara, M., Iwatsubo, T., & Tomita, T. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.12.087 · Cited by 37
Self-citationAssociation between acetylcholinesterase and β-amyloid peptide in Alzheimer's cerebrospinal fluid
García‐Ayllón, M., Silveyra, M. X., & Sáez‐Valero, J. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.04.047 · Cited by 37
Shimojo, M., Sahara, N., Mizoroki, T., Funamoto, S., Morishima‐Kawashima, M., Kudo, T., Takeda, M., Ihara, Y., Ichinose, H., & Takashima, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801279200 · Cited by 38
Self-citationKey Residues for the Formation of Aβ42 Amyloid Fibrils
Hsu, F., Park, G., & Guo, Z. (2018) · ACS Omega · doi:10.1021/acsomega.8b00887 · Cited by 38
Imperatore, J. A., Then, M. L., McDougal, K. B., & Mihailescu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030767 · Cited by 37
Yamashita, K., Watanabe, S., Ishiki, K., Miura, M., Irino, Y., Kubo, T., Matsui, J., Hagino, K., Iwanaga, S., & Yoshida, T. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.08.066 · Cited by 37
Keller, L., Welander, H., Chiang, H., Tjernberg, L. O., Nennesmo, I., Wallin, Å. K., & Graff, C. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.107 · Cited by 40
‘O-Acyl isopeptide method’ for the efficient preparation of amyloid β peptide 1–42 mutants
Sohma, Y., Chiyomori, Y., Kimura, M., Fukao, F., Taniguchi, A., Hayashi, Y., Kimura, T., & Kiso, Y. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.06.037 · Cited by 38
Morawski, M., Hartlage‐Rübsamen, M., Jäger, C., Waniek, A., Schilling, S., Schwab, C., McGeer, P. L., Arendt, T., Demuth, H., & Roßner, S. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0685-y · Cited by 37
Molecular Neurobiology of Alzheimer's Disease (Syndrome?)
Zubenko, G. S. (1997) · Harvard Review of Psychiatry · doi:10.3109/10673229709000303 · Cited by 37
Marciniuk, K., Taschuk, R., & Napper, S. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/473706 · Cited by 39
Amyloid β Protein in Plasma as a Diagnostic Marker for Alzheimer’s Disease
Iwatsubo, T. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00015-3 · Cited by 37
Self-citationVerbeek, M. M., Otte‐Höller, I., Wesseling, P., Ruiter, D. J., & de Waal, R. M. W. (1996) · Acta Neuropathologica · doi:10.1007/s004010050474 · Cited by 38
βAPP and Furin mRNA Concentrates in Immature Senile Plaques in the Brain of Alzheimer Patients
Marcinkiewicz, M. M. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.9.915 · Cited by 37
Cryo-EM structures of pathogenic fibrils and their impact on neurodegenerative disease research
Todd, T. W., Islam, N. N., Cook, C. N., Caulfield, T. R., & Petrucelli, L. (2024) · Neuron · doi:10.1016/j.neuron.2024.05.012 · Cited by 37
On the metal ion (Zn2+, Cu2+) coordination with beta-amyloid peptide: DFT computational study
Marino, T., Russo, N., Toscano, M., & Pavelka, M. (2010) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-010-0086-x · Cited by 35
Singh, R. R. P., Barman, A., & Prabhakar, R. S. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp811154w · Cited by 36
A potential therapeutic effect of saikosaponin C as a novel dual‐target anti‐Alzheimer agent
Lee, T. H., Park, S., You, M., Lim, J.-H., Min, S., & Kim, B. M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13515 · Cited by 37
Härtig, W., Brückner, G., Schmidt, C., Brauer, K., Bodewitz, G., Turner, J. D., & Bigl, V. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01423-0 · Cited by 37
Biological Markers in Alzheimer Disease
Neugroschl, J. A., & Davis, K. L. (2002) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200211000-00005 · Cited by 37
Lins, L., Thomas‐Soumarmon, A., Pillot, T., Vandekerckhove, J. S., Rosseneu, M., & Brasseur, R. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730758.x · Cited by 36
Docosahexaenoic acid withstands the Aβ25-35-induced neurotoxicity in SH-SY5Y cells
Hashimoto, M., Katakura, M., Hossain, S., Rahman, A., Shimada, T., & Shido, O. (2010) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.11.005 · Cited by 36
Takeda, A., Nakamura, M., Fujii, H., Uematsu, C., Minamino, T., Adlard, P. A., Bush, A. I., & Tamano, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115923 · Cited by 35
Lee, J., Kweon, H., Cho, E., Lee, J.-Y., Byun, H.-R., Kim, D. H., Kim, Y. H., Han, P., & Koh, J. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.06.037 · Cited by 36
Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease
Tomita, T. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.01.001 · Cited by 36
Dysregulated Metabolism of the Amyloid‐β Protein and Therapeutic Approaches in Alzheimer Disease
Kikuchi, K., Kidana, K., Tatebe, T., & Tomita, T. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26129 · Cited by 34
Oxidative stress and predominant Aβ42(43) deposition in myopathies with rimmed vacuoles
Tateyama, M., Takeda, A., Onodera, Y., Matsuzaki, M., Hasegawa, T., Nunomura, A., Hirai, K., Perry, G. L., Smith, M. A., & Itoyama, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0685-2 · Cited by 35
Klaver, A. C., Patrias, L. M., Coffey, M. P., Finke, J. M., & Loeffler, D. A. (2010) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.01.018 · Cited by 35
Dickkopf‐related protein 3 is a potential Aβ‐associated protein in Alzheimer's Disease
Bruggink, K. A., Kuiperij, H. B., Gloerich, J., Otte‐Höller, I., Rozemüller, A. J. M., Claassen, J. A. H. R., Küsters, B., & Verbeek, M. M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13216 · Cited by 35
Potter, H. (1998) · Frontiers in bioscience · doi:10.2741/a290 · Cited by 35
Processing of β-Amyloid Precursor Protein by Cathepsin D
Higaki, J. N., Catalano, R., Guzzetta, A. W., Quon, D. H., Navé, J.-F., Tarnus, C., d'Orchymont, H., & Cordell, B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.31885 · Cited by 35
The secretases of Alzheimer's disease
Wolfe, M. S. (2003) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(03)54011-x · Cited by 35
Uptake of Aβ 1–40- and Aβ 1–42-coated yeast by microglial cells: a role for LRP
Laporte, V., Lombard, Y., Levy-Benezra, R., Tranchant, C., Poindron, P., & Warter, J.-M. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.1203620 · Cited by 27
Kida, E., Wisniewski, K. E., & Wı́sniewski, H. M. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11678-p · Cited by 35
Terai, K., Iwai, A., Kawabata, S., Sasamata, M., Miyata, K., & Yamaguchi, T. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02202-8 · Cited by 36
Alzheimer s disease and heparan sulfate proteoglycan
Fukuchi, K.-I. (1998) · Frontiers in bioscience · doi:10.2741/a277 · Cited by 35
Metadata
- Authors
- Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y.
- Affiliations
- Takeda (Japan) (JP)
- The University of Tokyo (JP)
- University of Tsukuba (JP)
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 1994-07
- Volume
- 13
- Issue
- 1
- Pages
- 45-53
- ISSN
- 0896-6273 (ISSN-L)
- OpenAlex
- W1991435932
- Cited by
- 1,774
- References
- 41
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 53 · 2023: 49 · 2022: 49 · 2021: 55 · 2020: 68 · 2019: 49 · 2018: 41 · 2017: 49 · 2016: 52 · 2015: 45 · 2014: 68 · 2013: 69 · 2012: 66
- FWCI
- 35.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, Aβ40, amyloid plaques, Alzheimer's disease, familial Alzheimer's disease, plaque maturation, diffuse plaques, immunocytochemistry
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Antibodies, Monoclonal, Brain, Cerebral Cortex, Female, Humans, Immunoenzyme Techniques, Male, Middle Aged, Mutation, Peptide Fragments, Amyloid beta-Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
